Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study.

Cancer Medicine
Hanping WangLi Zhang

Abstract

The increasing application of immune checkpoint inhibitors (ICIs) will cause more checkpoint inhibitor-related pneumonitis (CIP), which is a common cause of ICI-related death. The clinical management of CIP needs further optimization. Patients who were managed at Peking Union Medical College Hospital (PUMCH) between February 2017 and December 2019 with a diagnosis of CIP were retrospectively analyzed. Clinical data including clinical manifestations, radiologic data, laboratory and bronchoscopy results, treatments, and outcomes were collected and analyzed. The Mann-Whitney test was used to compare patients with and without co-infections. In total, 48 CIP cases in 42 patients were analyzed. The median time from the first dose of ICI to the onset of CIP was 1.9 months (range: 0.1-13.7). Grade 3-4 (G3-4) accounted for 30 cases (71.4%). The most common symptoms were cough (88.1%) and dyspnea (78.6%). The median starting dose of equivalent prednisone (EP) was 55 mg (range: 30-200) for all patients. The median total duration of glucocorticosteroids (GCS) treatment was 42.5 days (range: 15-89). Three patients (7.14%) died because of infection. A higher starting dose and longer duration of GCS (≥30 mg/day; p = 0.001) were associated wit...Continue Reading

References

Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Sep 17, 2013·American Journal of Respiratory and Critical Care Medicine·William D TravisUNKNOWN ATS/ERS Committee on Idiopathic Interstitial Pneumonias
Feb 25, 2015·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Li-Ching ChewJulian Thumboo
Nov 28, 2015·Rheumatic Diseases Clinics of North America·Jameel YoussefKevin L Winthrop
Jun 17, 2016·Annals of the Rheumatic Diseases·Laura C CappelliClifton O Bingham
Aug 19, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mizuki NishinoF Stephen Hodi
Sep 21, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jarushka NaidooMatthew D Hellmann
Aug 12, 2017·The European Respiratory Journal·Myriam DelaunayJulien Mazieres
Jan 11, 2018·The New England Journal of Medicine·Michael A PostowMatthew D Hellmann
Feb 15, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerUNKNOWN National Comprehensive Cancer Network
Nov 16, 2018·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jun Yeun ChoJong Sun Park
Nov 5, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aurelien MarabelleLuis A Diaz
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B A G HaanenUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

❮ Previous
Next ❯

Citations

Aug 16, 2021·European Journal of Internal Medicine·Corrado CampochiaroLorenzo Dagna

❮ Previous
Next ❯

Methods Mentioned

BETA
ESR

Software Mentioned

SPSS Statistics

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.